EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Prevention of development of type 1 diabetes in NOD mice by targeting Janus kinase 3 with 4- -amino-6,7-dimethoxyquinazoline



Prevention of development of type 1 diabetes in NOD mice by targeting Janus kinase 3 with 4- -amino-6,7-dimethoxyquinazoline



Diabetes Research & Clinical Practice 50(Suppl 1): S183, September




(PDF emailed within 1 workday: $29.90)

Accession: 035551135

Download citation: RISBibTeXText



Related references

Prevention of islet allograft rejection in diabetic mice by targeting Janus kinase 3 with 4- -amino-6,7-dimethoxyquinazoline. Arzneimittel-Forschung 53(9): 648-654, 2003

Prevention of islet allograft rejection in diabetic mice by targeting Janus Kinase 3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1). Arzneimittel-Forschung 53(9): 648-654, 2003

Targeting Janus kinase 3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. Diabetes 52(Supplement 1): A274-A275, 2003

Prevention of fatal thromboembolism in mice by selectively targeting Jak 3 kinase in platelets with 4- -amino-6,7-dimethoxyquinazoline. Blood 96(11 Part 1): 273a, November 16, 2000

Islet allograft rejection is prevented by targeting Janus kinase 3 with 4- -amino-6,7-dimethoxyquinazoline. Diabetes Research & Clinical Practice 50(Suppl 1): S183, September, 2000

Treatment of allergic asthma by targeting Janus kinase 3-dependent leukotriene synthesis in mast cells with 4- amino-6,7-dimethoxyquinazoline. Journal of Pharmacology & Experimental Therapeutics 295(3): 912-926, December, 2000

Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). Journal of Pharmacology and Experimental Therapeutics 295(3): 912-926, 2000

Pharmacokinetics and in vivo toxicity of Janus kinase 3 inhibitor WHI-P131 -amino-6,7-Dimethoxyquinazoline. Blood 94(10 SUPPL 1 PART 2): 197b, Nov 15, 1999

In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline. Clinical Cancer Research 5(10): 2954-2962, 1999

CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: structural basis for inactivation by regioselective O-demethylation. Drug Metabolism and Disposition: the Biological Fate of Chemicals 30(1): 74-85, 2001

CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: Structural basis for inactivation by regioselective O-demethylation. Drug Metabolism and Disposition 30(1): 74-85, 2002

Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. Clinical Immunology (Orlando) 106(3): 213-225, March, 2003

Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154). Clinical Cancer Research 4(10): 2463-2471, 1998

Prevention of UVB-induced skin inflammation, genotoxicity, and photocarcinogenesis in mice by WHI-P131, a dual-function inhibitor of Janus kinase 3 and EGF receptor kinase. Arzneimittel-Forschung 60(4): 218-225, 2010

Janus reveals another face: the biologic rationale for targeting Janus kinase 2 in lymphoma. Journal of Clinical Oncology 30(33): 4168-4170, 2013